Plasma ECRG4 as a novel diagnostic marker for Alzheimer's disease associated with oligodendrocyte dysfunction
Abstract
) mRNA, which is mainly expressed in oligodendrocyte (OLG)-lineage cells, in ECRG4-positive patients. Functional analyses demonstrated that the ECRG4 (71-107) peptide induced cytotoxicity in oligodendrocytes in vitro and reduced the expression of the OLG marker galactocerebroside in the corpus callosum following intracerebral injection. Additionally, peptide injection resulted in extravascular IgG leakage and the accumulation of OLG precursor cells (OPCs), which are crucial for myelin regeneration, around the blood vessels. These phenomena were similarly observed in the hippocampi of patients with EAD. Collectively, these findings establish ECRG4 as a novel serum marker for AD and suggest its association with ECRG4-dependent OLG dysfunction.
Fields of Study & Subjects
Neurogenesis and neuroplasticity mechanisms
Epigenetics and DNA Methylation
Congenital heart defects research
Publication details
- Journal / source
- American Journal of Translational Research
- Publisher
- e-Century Publishing Corporation
- Volume
- 18
- Issue
- 5
- Pages
- 3765–3782
- Publication date
- 1 January 2026
- Language
- EN